Literature DB >> 9261375

Activation domain requirements for disruption of Epstein-Barr virus latency by ZEBRA.

S Asković1, R Baumann.   

Abstract

Latent infection of B lymphocytes by Epstein-Barr virus (EBV) can be disrupted by expression of the EBV ZEBRA protein. ZEBRA, a transcriptional activator, initiates the EBV lytic cascade by activating viral gene expression. ZEBRA is also indispensable for viral replication and binds directly to the EBV lytic origin of replication. The studies described herein demonstrate that the activation domain. ZEBRA activation can be replaced by a heterologous acidic, proline-rich, or glutamine-rich activation domain. ZEBRA activation domain swap constructs retain ZEBRA's native abilities to activate specific EBV promoters, to disrupt EBV latency, and to stimulate replication at the EBV lytic origin. Additional work, employing sequential and internal deletions of ZEBRA's N-terminal activation domain, indicates that its separate activities are not attributable to specific subdomains but are spread throughout its N terminus and therefore cannot be inactivated by deleting localized regions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9261375      PMCID: PMC191931     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  The Zta trans-activator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction.

Authors:  P M Lieberman; A J Berk
Journal:  Genes Dev       Date:  1991-12       Impact factor: 11.361

2.  Alternative system for detection and mapping of activation domains.

Authors:  S Asković; R Baumann
Journal:  Biotechniques       Date:  1997-05       Impact factor: 1.993

3.  The ZEBRA activation domain: modular organization and mechanism of action.

Authors:  T Chi; M Carey
Journal:  Mol Cell Biol       Date:  1993-11       Impact factor: 4.272

4.  Changing Epstein-Barr viral ZEBRA protein into a more powerful activator enhances its capacity to disrupt latency.

Authors:  R Baumann; E Grogan; M Ptashne; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

5.  cis-acting elements in the lytic origin of DNA replication of Epstein-Barr virus.

Authors:  A Schepers; D Pich; J Mankertz; W Hammerschmidt
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

6.  trans-acting requirements for replication of Epstein-Barr virus ori-Lyt.

Authors:  E D Fixman; G S Hayward; S D Hayward
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

7.  Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection.

Authors:  N D Sista; J S Pagano; W Liao; S Kenney
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

8.  Molecular cloning and functional analysis of Drosophila TAF110 reveal properties expected of coactivators.

Authors:  T Hoey; R O Weinzierl; G Gill; J L Chen; B D Dynlacht; R Tjian
Journal:  Cell       Date:  1993-01-29       Impact factor: 41.582

9.  Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells.

Authors:  M Rabson; L Heston; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

10.  A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus.

Authors:  A Schepers; D Pich; W Hammerschmidt
Journal:  EMBO J       Date:  1993-10       Impact factor: 11.598

View more
  5 in total

1.  Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.

Authors:  A L Adamson; S Kenney
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Activation of the Epstein-Barr virus transcription factor BZLF1 by 12-O-tetradecanoylphorbol-13-acetate-induced phosphorylation.

Authors:  M Baumann; H Mischak; S Dammeier; W Kolch; O Gires; D Pich; R Zeidler; H J Delecluse; W Hammerschmidt
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  Interaction with the Epstein-Barr virus helicase targets Zta to DNA replication compartments.

Authors:  G Liao; F Y Wu; S D Hayward
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  The Epstein-Barr virus lytic transactivator Zta interacts with the helicase-primase replication proteins.

Authors:  Z Gao; A Krithivas; J E Finan; O J Semmes; S Zhou; Y Wang; S D Hayward
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

5.  Mta has properties of an RNA export protein and increases cytoplasmic accumulation of Epstein-Barr virus replication gene mRNA.

Authors:  O J Semmes; L Chen; R T Sarisky; Z Gao; L Zhong; S D Hayward
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.